November 20, 2013
Canada is the first market launch for JETREA
outside the US and Europe
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA® (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA) in
is the first market where JETREA® has been launched outside the US and
Symptomatic VMA is estimated to affect up to 15,000 people in
August 13, 2013
following priority review.
Alcon, a division of Novartis, acquired the rights to commercialize JETREA
the United States
. It launched the drug in the UK, its first European market, in April, followed by launches in
ThromboGenics is commercializing the drug in the US and launched JETREA
in the US in
where it is approved for the treatment of patients with symptomatic vitreomacular adhesion (VMA).
Dr Patrik De Haes, CEO of ThromboGenics, says:
The launch of JETREA
in Canada, the first market outside the US and Europe, is an another important step in the global roll out of this innovative new drug for the treatment of symptomatic VMA. This is a condition where early pharmacological treatment is being seen as increasingly important in potentially preventing patients
loss of visual acuity which negatively impacts on their ability to carry out everyday tasks. We are looking forward to working with Alcon as it continues to roll out
in other European and Rest of the World markets.
contains the active substance ocriplasmin. It is administered through a one-time, single intravitreal injection to treat adults with symptomatic VMA.
Symptomatic VMA is an age-related progressive, sight-threatening condition. It is caused by the vitreous having an abnormally strong attachment to the central part of the retina (the light sensitive membrane at the back of the eye). The macula provides central vision that is needed for everyday tasks such as driving, reading and recognizing faces.